

Risk assessing your research: is it really worth pursuing into a business?

with Barbara Diehl, Peter Mumford and Julia Wagner

Curious if your clinical research has real-world business potential? Join our panel discussion in unpacking how to navigate risk assessment and make confident, informed decisions about turning academic science into a viable commercial venture.



Barbara is a proven expert in entrepreneurship, innovation and education. In Oxford, she led early-stage investment programs and an executive education program for fast-growing small businesses. Following her return to Germany, she served as Director of Transfer and Innovation at the Helmholtz Association of German Research Centres, and now works at SPRIN-D, the German Federal Agency for Breakthrough Innovation.

Peter is a UK and European patent attorney specialising in chemical inventions, particularly small molecule therapeutics, pharmaceutical formulations, and new medical uses. He works with a broad range of clients, with considerable experience of helping spin-off and start-up life science companies to prepare for fundraising as well as due diligence for investors.



Julia is an investor at Positron Ventures, focusing on early-stage deep tech start-ups across Europe. She is passionate about turning breakthrough science into scalable companies, holds a PhD from ETH Zurich, and previously built a student-led venture fund investing in university spin-offs.

Register here

3rd July 2025

4 - 5pm CET (3 - 4pm BST)